Guggenheim Reiterates Buy Rating for Dianthus Therapeutics (DNTH) [Yahoo! Finance]
Dianthus Therapeutics, Inc. (DNTH)
Company Research
Source: Yahoo! Finance
On March 4, Guggenheim increased the price target on Dianthus Therapeutics Inc. (NASDAQ:DNTH) to $200 from $100. The firm maintains its Buy rating on the stock with an upside potential of almost 207%. The adjustment follows updates to the firm's model, which raised its estimates for claseprubart. Guggenheim now projects approximately $2.8 billion in global peak sales from CIDP patients and estimates around $2 billion in global sales from the gMG indication. On January 29, Oppenheimer increased its price target on Dianthus Therapeutics Inc. (NASDAQ:DNTH) to $125 from $62 while maintaining an Outperform rating. The firm points out that Dianthus shares have gained 22% year to date, compared with XBI's 5% rise. This is primarily due to the comments from CEO Marino Garcia during the January healthcare conference on the potential superiority of the company's product over the competitor's complement inhibitors. Guggenheim Reiterates Buy Rating for Dianthus Therapeutics (DNTH) Dianth
Show less
Read more
Impact Snapshot
Event Time:
DNTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNTH alerts
High impacting Dianthus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DNTH
News
- Dianthus Therapeutics (DNTH) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $135.00 price target on the stock.MarketBeat
- Wedbush Keeps Outperform on Dianthus Therapeutics, Inc. (DNTH), Highlights Potential of Claseprubart in CIDP [Yahoo! Finance]Yahoo! Finance
- Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit [Yahoo! Finance]Yahoo! Finance
- Dianthus Therapeutics (DNTH) had its "outperform" rating reaffirmed by William Blair.MarketBeat
- Dianthus Therapeutics Hits Early “Go” in CAPTIVATE Phase 3 CIDP Trial, Drops 600 mg Arm [Yahoo! Finance]Yahoo! Finance
DNTH
Earnings
- 3/9/26 - Miss
DNTH
Sec Filings
- 3/26/26 - Form 4
- 3/26/26 - Form 8-K
- 3/24/26 - Form 144
- DNTH's page on the SEC website